Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-07-22EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
The EMA authorises Braftovi (encorafenib) for melanoma and colorectal neoplasms.
-
EMA approval · 2026-07-21EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG
Opdualag, a nivolumab and relatlimab combination, has been authorised for melanoma in the EU.
-
EMA approval · 2026-07-01EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
EMA authorises Braftovi (Encorafenib) for melanoma and colorectal neoplasms.
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-06-24EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision d…
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
EMA approval · 2026-04-09EMA Authorised: Tafinlar (dabrafenib mesilate) — Novartis Europharm Limited
The European Medicines Agency authorised Tafinlar, with the active substance dabrafenib mesilate, for melanoma; the marketing authorization …
-
EMA approval · 2026-04-07EMA Authorised: Opdualag (nivolumab;relatlimab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Opdualag, a fixed-dose combination of nivolumab and relatlimab, for melanoma, with Bristol-Myers Sq…
-
EMA approval · 2026-01-06EMA Authorised: Imlygic (talimogene laherparepvec) — Amgen Europe B.V.
The EMA authorised Imlygic (talimogene laherparepvec) for melanoma, with Amgen Europe B.V. as the marketing authorisation holder; decision d…
-
EMA approval · 2025-11-21EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…
-
EMA approval · 2025-11-13EMA Authorised: Mekinist (trametinib) — Novartis Europharm Limited
The EMA authorised Mekinist (trametinib) for melanoma; the marketing authorisation holder is Novartis Europharm Limited.
-
EMA approval · 2025-11-05EMA Authorised: Mektovi (binimetinib) — Pierre Fabre Medicament
The European Medicines Agency has authorised Mektovi (binimetinib) for melanoma, with Pierre Fabre Medicament as the marketing authorization…
-
EMA approval · 2025-11-05EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
The EMA authorised Braftovi (encorafenib) for melanoma and colorectal cancer. Pierre Fabre Medicament is the marketing authorization holder.
-
EMA approval · 2025-06-24EMA Authorised: Cotellic (cobimetinib hemifumarate) — Roche Registration GmbH
EMA authorised Cotellic (cobimetinib hemifumarate) for melanoma; the marketing authorisation holder is Roche Registration GmbH with a decisi…
-
EMA approval · 2025-06-19EMA Authorised: Zelboraf (vemurafenib) — Roche Registration GmbH
The European Medicines Agency authorised Zelboraf (vemurafenib) by Roche Registration GmbH for melanoma.
-
FDA approval · 2025-05-23FDA Approved: YERVOY — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for YERVOY (ipilimumab) by E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2025-03-19FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TAFINLAR (dabrafenib) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2025-03-07FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA supplemental application for TAFINLAR (dabrafenib) submitted by Novartis Pharmaceuticals Corporation to seek changes to the drug's label…
-
FDA approval · 2024-09-12FDA Approved: MEKTOVI — Supplemental Application (Array BioPharma Inc.)
FDA approved a supplemental application for MEKTOVI (binimetinib) submitted by Array BioPharma Inc.
-
FDA approval · 2024-03-06FDA Approved: OPDUALAG — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA has approved a supplemental application for OPDUALAG (nivolumab and relatlimab-rmbw) submitted by E.R. Squibb & Sons, L.L.C. The documen…
-
FDA approval · 2024-02-27FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for MEKINIST (trametinib) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-10-11FDA Approved: BRAFTOVI — Supplemental Application (Array BioPharma Inc.)
The FDA approved a supplemental application for BRAFTOVI (encorafenib) submitted by Array BioPharma Inc., updating the drug's labeling or in…
-
FDA approval · 2023-09-29FDA Approved: PROLEUKIN — Supplemental Application (Iovance Biotherapeutics, Inc)
The FDA has approved a supplemental application for PROLEUKIN (aldesleukin) submitted by Iovance Biotherapeutics, Inc.
-
FDA approval · 2023-06-14FDA Approved: IMJUDO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for IMJUDO (tremelimumab) from AstraZeneca.